Journal article

Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy

Yanina Ghiglione, Maria Laura Polo, Alejandra Urioste, Ajantha Rhodes, Alejandro Czernikier, Cesar Trifone, Maria Florencia Quiroga, Alicia Sisto, Patricia Patterson, Horacio Salomon, Maria Jose Rolon, Sonia Bakkour, Sharon R Lewin, Gabriela Turk, Natalia Laufer

OPEN FORUM INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2020

Abstract

Background: Hepatitis C virus (HCV) coinfection among people with human immunodeficiency virus (HIV) might perturb immune function and HIV persistence. We aimed to evaluate the impact of HCV clearance with direct-acting antivirals (DAAs) on immune activation and HIV persistence in HIV/HCV-coinfected individuals on antiretroviral therapy (ART). Methods: In a prospective observational study, ART-treated participants with HIV/HCV coinfection received sofosbuvir/daclatasvir ± ribavirin (n = 19). Blood samples were collected before DAA therapy, at the end of treatment, and 12 months after DAA termination (12MPT). T- and natural killer (NK)-cell phenotype, soluble plasma factors, cell-associated (..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Institutes for Health Delaney AIDS Research Enterprise (DARE) Collaboratory


Awarded by Consejo Nacional de Investigaciones Cientificas y Tecnicas


Awarded by Agencia Nacional de Promocion Cientifica y Tecnologica (PICT2016)


Awarded by ViiV Healthcare Investigator Sponsored Studies


Funding Acknowledgements

S. R. L. is funded by the National Health and Medical Research Council of Australia and the National Institutes for Health Delaney AIDS Research Enterprise (DARE) Collaboratory (U19 A1096109, UM1AI126611]). This work was funded by grants from Consejo Nacional de Investigaciones Cientificas y Tecnicas (Grant Number PUE2016-INBIRS), the Agencia Nacional de Promocion Cientifica y Tecnologica (PICT2016, Grant Number 930), ViiV Healthcare Investigator Sponsored Studies (reference number 209424), and Fundacion Florencio Fiorini.